These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

846 related items for PubMed ID: 32685029

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
    Ullah R, Wazir J, Khan FU, Diallo MT, Ihsan AU, Mikrani R, Aquib M, Zhou X.
    AAPS PharmSciTech; 2020 May 14; 21(4):132. PubMed ID: 32409932
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D, Zhou S, Gao W.
    ACS Nano; 2020 Oct 27; 14(10):12281-12290. PubMed ID: 33021091
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
    Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC.
    Cancer Res; 2013 Apr 15; 73(8):2412-7. PubMed ID: 23423979
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effects of tumor microenvironments on targeted delivery of glycol chitosan nanoparticles.
    Yhee JY, Jeon S, Yoon HY, Shim MK, Ko H, Min J, Na JH, Chang H, Han H, Kim JH, Suh M, Lee H, Park JH, Kim K, Kwon IC.
    J Control Release; 2017 Dec 10; 267():223-231. PubMed ID: 28917532
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
    Nakamura H, Fang J, Maeda H.
    Expert Opin Drug Deliv; 2015 Jan 10; 12(1):53-64. PubMed ID: 25425260
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Actively Targeted Nanoparticles for Drug Delivery to Tumor.
    Bi Y, Hao F, Yan G, Teng L, Lee RJ, Xie J.
    Curr Drug Metab; 2016 Jan 10; 17(8):763-782. PubMed ID: 27335116
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Monitoring EPR Effect Dynamics during Nanotaxane Treatment with Theranostic Polymeric Micelles.
    Biancacci I, De Lorenzi F, Theek B, Bai X, May JN, Consolino L, Baues M, Moeckel D, Gremse F, von Stillfried S, El Shafei A, Benderski K, Azadkhah Shalmani A, Wang A, Momoh J, Peña Q, Buhl EM, Buyel J, Hennink W, Kiessling F, Metselaar J, Shi Y, Lammers T.
    Adv Sci (Weinh); 2022 Apr 10; 9(10):e2103745. PubMed ID: 35072358
    [Abstract] [Full Text] [Related]

  • 40. Physical oncology: New targets for nanomedicine.
    Nicolas-Boluda A, Silva AKA, Fournel S, Gazeau F.
    Biomaterials; 2018 Jan 10; 150():87-99. PubMed ID: 29035739
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.